Field emission of ZnO nano-structures produced by laser ablation

The thesis describes the development of, and results from, two new laboratory facilities designed to investigate the properties of laser produced plasmas, with in-situ time of flight mass spectrometry, for deposition of ZnO materials for applications as field electron emission sources. The results from the work are concerned with the study of the important physical processes present in a laser ablation zinc oxide plasma plume expanding into vacuum and various ambient gas pressures. The thesis also demonstrated the advantages of combining a linear ToF detector and a mass resolved ReToF spectrometer for clarification of ionisation processes in the pulsed laser ablation regime of solid targets. The outstanding results show that during the ablation process, ZnO atomises into Zn and O. In the vacuum regime we have shown that at long distances from the target multiple charged states of Zn and O are present. While under the same conditions in an ambient gas the multiple charged states are not present, however the ambient gas undergoes an ionisation process. Deposited materials are tested for applications as field electron emission sources, for analysis of field enhancement factors from nano-material ZnO

A new technique for the determination of the critical current density in superconducting films and flat samples

The determination of their critical current density in the whole range of the temperature below Tc is of first importance to understand the physical processes occurring in superconducting films. We describe here a technique suitable for square films based on the measurement of the magnetic moment due to the currents persisting in the superconductor after the application of a perpendicular high magnetic field. Typically, with a SQUID magnetometer, the measurement time in the whole range of temperature with a 1K interval is of 2 hours only by this technique. An intriguing aspect of the obtained results is that they are much more accurate if the current lines are supposed to be circular than if we suppose, as suggested by theoretical considerations and magneto-optical observations that they have the sample symmetry

Emission characteristics and dynamics of the stagnation layer in colliding laser produced plasmas

The expansion dynamics of ion and neutral species in laterally colliding laser produced aluminum plasmas have been investigated using time and space resolved optical emission spectroscopies and spectrally and angularly resolved fast imaging. The emission results highlight a difference in neutral atom and ion distributions in the stagnation layer where, at a time delay of 80 ns, the neutral atoms are localized in the vicinity of the target surface 1 mm from the target surface while singly and doubly charged ions lie predominantly at larger distances, 1.5 and 2 mm, respectively. The imaging results show that the ions were found to form a well defined, but compressed, stagnation layer at the collision front between the two seed plasmas at early times (Dt ~ 80 ns). On the other hand, the excited neutrals were observed to form a V-shaped emission feature at the outer regions of the collision front with enhanced neutral emission in the less dense, cooler regions of the stagnation layer

The Viability of Organic Dyes in Luminescent Down-Shifting Layers for the Enhancement of Si Solar Cell Efficiency

The main energy losses in solar cells are related to spectral losses where high energy photons are not used efficiently, and energy is lost via thermalization which reduces the solar cell’s overall efficiency. A way to tackle this is to introduce a luminescent down-shifting layer (LDS) to convert these high energy photons into a lower energy bracket helping the solar cell to absorb them and thus generating a greater power output. In this paper, lumogen dye Violet 570 has been used as LDS coated films of 10μm and 60μm placed on top of Si solar cells. The dye was incorporated into polymer films of Polyvinyl Butyral (PVB) and Polymethyl Methacrylate (PMMA) after which they were tested for their absorption, transmission and emission properties. Once optimised layers had been determined, they were deposited directly onto silicon solar cells and the external quantum efficiency (EQE) of the Si solar cells were measured with and without the LDS layers. The resulting graphs have shown an increase of up to 2.9% in the overall EQE efficiency after the lumogen films had been applied

Growth and Field Emission Properties of ZnO Nanostructures Deposited by a Novel Pulsed Laser Ablation Source on Silicon Substrates

Zinc oxide (ZnO) nanostructures were produced using a novel pulsed laser ablation apparatus comprising in-situ analysis of the plume by reflection time-of-flight mass spectrometry. Various morphologies of nano and microstructures were obtained for laser wavelengths of 1064 nm and 355 nm, and oxygen ambient pressures of 10-6 mbar and 10-2 mbar, respectively. None of the produced structures exhibited a particular type of self organisation whereas all of them showed low aspect ratios and good field emission properties. Optimum values of 5.2 Vμm-1 and 2060 were obtained for the turn-on field and Fowler-Nordheim enhancement factor, respectively, for deposited nano-tipped microstructures presenting a high coverage of the substrate. The experimental data showed that for a given laser wavelength, higher field enhancement factors were obtained for the samples grown at the lower pressure of 10-6 mbar. In these conditions, the deposited materials showed distinct nanostructuring and comparison with existing data showed the corresponding ablation plumes to contain (ZnO)n clusters, up to n=13. This work also shows that the electronic properties of the nanostructured ZnO produced in our conditions, as determined by the oxygen concentration during deposition, have an influence on the field emission properties in addition to the nanostructure morphology

The emergence of a climate change signal in long-term Irish meteorological observations

Detecting the emergence of a forced anthropogenic climate change signal from observations is critical for informing adaptation responses. By regressing local variations in climate onto annual Global Mean Surface Temperature (GMST), we track the emergence of an anthropogenic signal in long-term quality assured observations of temperature and precipitation for the island of Ireland, a sentinel location on the western European Atlantic seaboard. Analysis of station based observations, together with island scale composite series is undertaken for annual and seasonal means, together with 16 indices of extremes, with the derived signal-to-noise ratio classified as normal, unusual or unfamiliar relative to early industrial climate. More than half of indices show the emergence of at least unusual conditions relative to early industrial climate. The increase in annual mean temperature has led to the emergence of unfamiliar climate at six of eleven stations. Warming at the island scale is estimated at 0.88 °C per degree warming in GMST. While many stations show the emergence of unusual climate for spring, summer and autumn mean temperature, no forced signal of change is found for winter mean temperature. Changes in cool/warm days and nights are unfamiliar relative to early industrial climate. However, no anthropogenic signal is found for the hottest day annually or in summer – an extreme often associated with climate change in public consciousness. Increases in annual precipitation totals have emerged as unusual for western stations with large increases in winter totals per degree warming in GMST (e.g., 25.2% and 19.7% at Malin Head and Markree, respectively), indicating heightened flood risk with continued warming. By contrast, summer precipitation shows no significant relationship with GMST. Increases in rainfall intensity have emerged as unusual for 30% of stations, with increases consistent with the Clausius-Clapeyron relationship. Our analysis shows that an emerging climate change signal is discernible for Ireland, a location strongly influenced by climate variability

Phenotypic Complexity, Measurement Bias, and Poor Phenotypic Resolution Contribute to the Missing Heritability Problem in Genetic Association Studies

Background The variance explained by genetic variants as identified in (genome-wide) genetic association studies is typically small compared to family-based heritability estimates. Explanations of this ‘missing heritability’ have been mainly genetic, such as genetic heterogeneity and complex (epi-)genetic mechanisms. Methodology We used comprehensive simulation studies to show that three phenotypic measurement issues also provide viable explanations of the missing heritability: phenotypic complexity, measurement bias, and phenotypic resolution. We identify the circumstances in which the use of phenotypic sum-scores and the presence of measurement bias lower the power to detect genetic variants. In addition, we show how the differential resolution of psychometric instruments (i.e., whether the instrument includes items that resolve individual differences in the normal range or in the clinical range of a phenotype) affects the power to detect genetic variants. Conclusion We conclude that careful phenotypic data modelling can improve the genetic signal, and thus the statistical power to identify genetic variants by 20-99

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

Background: This analysis assessed, on a group level, whether there is a long-term advantage for early RA patients treated with adalimumab (ADA) + MTX vs those initially treated with placebo (PBO) + MTX who either responded to therapy or added ADA following inadequate response (IR). Methods: OPTIMA was a 78- week, randomized, controlled trial of ADA + MTX vs PBO + MTX in MTX-naïve early (<1 year) RA patients. Therapy was adjusted at week 26: ADA + MTX-responders (R) who achieved DAS28 (CRP) <3.2 at weeks 22 and 26 (Period 1, P1) were re-randomized to withdraw or continue ADA and PBO + MTX-R continued randomized therapy for 52 weeks (P2); IR-patients received open-label (OL) ADA + MTX during P2. This post hoc analysis evaluated the proportion of patients at week 78 with DAS28 (CRP) <3.2, HAQ-DI <0.5, and/or ΔmTSS ≤0.5 by initial treatment. To account for patients who withdrew ADA during P2, an equivalent proportion of R was imputed from ADA + MTX-R patients. Results: At week 26, significantly more patients had low disease activity, normal function, and/or no radiographic progression with ADA + MTX vs PBO + MTX (Table 1). Differences in clinical and functional outcomes disappeared following additional treatment, when PBO + MTX-IR (n = 348/460) switched to OL ADA + MTX. Addition of OL ADA slowed radiographic progression, but more patients who received ADA + MTX from baseline had no radiographic progression at week 78 than patients who received initial PBO + MTX. Conclusions: Early RA patients treated with PBO + MTX achieved comparable long-term clinical and functional outcomes on a group level as those who began ADA + MTX, but only when therapy was optimized by the addition of ADA in PBO + MTX-IR. Still, ADA + MTX therapy conferred a radiographic benefit although the difference did not appear to translate to an additional functional benefit. Disclosures: P.E., AbbVie, Merck, Pfizer, UCB, Roche, BMS—Provided Expert Advice, Undertaken Trials, AbbVie—AbbVie sponsored the study, contributed to its design, and participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final version. R.F., AbbVie, Pfizer, Merck, Roche, UCB, Celgene, Amgen, AstraZeneca, BMS, Janssen, Lilly, Novartis—Research Grants, Consultation Fees. S.F., AbbVie—Employee, Stocks. A.K., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, UCB—Research Grants, Consultation Fees. H.K., AbbVie—Employee, Stocks. S.R., AbbVie—Employee, Stocks. J.S., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, GlaxoSmithKline, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz, UCB—Research Grants, Consultation Fees. R.V., AbbVie, BMS, GlaxoSmithKline, Human Genome Sciences, Merck, Pfizer, Roche, UCB Pharma—Consultation Fees, Research Support. Table 1.Week 78 clinical, functional, and radiographic outcomes in patients who received continued ADA + MTX vs those who continued PBO + MTX or added open-label ADA following an inadequate response ADA + MTX, n/N (%)a PBO + MTX, n/N (%)b Outcome Week 26 Week 52 Week 78 Week 26 Week 52 Week 78 DAS28 (CRP) <3.2 246/466 (53) 304/465 (65) 303/465 (65) 139/460 (30)*** 284/460 (62) 300/460 (65) HAQ-DI <0.5 211/466 (45) 220/466 (47) 224/466 (48) 150/460 (33)*** 203/460 (44) 208/460 (45) ΔmTSS ≤0.5 402/462 (87) 379/445 (86) 382/443 (86) 330/459 (72)*** 318/440 (72)*** 318/440 (72)*** DAS28 (CRP) <3.2 + ΔmTSS ≤0.5 216/462 (47) 260/443 (59) 266/443 (60) 112/459 (24)*** 196/440 (45) 211/440 (48)*** DAS28 (CRP) <3.2 + HAQ-DI <0.5 + ΔmTSS ≤0.5 146/462 (32) 168/443 (38) 174/443 (39) 82/459 (18)*** 120/440 (27)*** 135/440 (31)** aIncludes patients from the ADA Continuation (n = 105) and OL ADA Carry On (n = 259) arms, as well as the proportional equivalent number of responders from the ADA Withdrawal arm (n = 102). bIncludes patients from the MTX Continuation (n = 112) and Rescue ADA (n = 348) arms. Last observation carried forward: DAS28 (CRP) and HAQ-DI; Multiple imputations: ΔmTSS. ***P < 0.001 and **iP < 0.01, respectively, for differences between initial treatments from chi-squar

RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy

Amyotrophic lateral sclerosis (ALS) presents with focal muscle weakness due to motor neuron degeneration that becomes generalized,leading to death from respiratory failure within 3–5 years from symptom onset. Despite the heterogeneity of aetiology, TDP- 43 proteinopathy is a common pathological feature that is observed in 495% of ALS and tau-negative frontotemporal dementia(FTD) cases. TDP-43 is a DNA/RNA-binding protein that in ALS and FTD translocates from being predominantly nuclear to formdetergent-resistant, hyperphosphorylated aggregates in the cytoplasm of affected neurons and glia. Mutations in TARDBP accountfor 1–4% of all ALS cases and almost all arise in the low complexity C-terminal domain that does not affect RNA binding andprocessing. Here we report an ALS/FTD kindred with a novel K181E TDP-43 mutation that is located in close proximity to the RRM1 domain. To offer predictive gene testing to at-risk family members, we undertook a series of functional studies to characterizethe properties of the mutation. Spectroscopy studies of the K181E protein revealed no evidence of significant misfolding.Although it is unable to bind to or splice RNA, it forms abundant aggregates in transfected cells. We extended our study to includeother ALS-linked mutations adjacent to the RRM domains that also disrupt RNA binding and greatly enhance TDP-43 aggregation,forming detergent-resistant and hyperphosphorylated inclusions. Lastly, we demonstrate that K181E binds to, and sequesters, wild-type TDP-43 within nuclear and cytoplasmic inclusions. Thus, we demonstrate that TDP-43 mutations that disrupt RNAbinding greatly enhance aggregation and are likely to be pathogenic as they promote wild-type TDP-43 to mislocalize andaggregate acting in a dominant-negative manner. This study highlights the importance of RNA binding to maintain TDP-43solubility and the role of TDP-43 aggregation in disease pathogenesis